{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"72.6","upperLimit":"97.8","value":"89.7"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"29"}],"units":"Participants"}],"description":"Major Cytogenetic Response (MCyR) rate is defined as the proportion of all treated participants who achieved a complete (0%) or partial (1%-35% Ph+ metaphases in at least 20 metaphases in bone marrow) cytogenetic response, expressed as percentage. The denominator of the MCyR response rate consists of all treated participants in Cohort 1, and the numerator is all participants in Cohort 1 achieving MCyR. 95% confidence interval was calculated by Clopper-Pearson exact method.","dispersionType":"95% Confidence Interval","groups":[{"description":"Children and adolescents with CP-CML who were resistant or intolerant to imatinib received dasatinib tablets at 60 mg/m2 QD on a continuous oral regimen.","id":"OG000","title":"Cohort 1"}],"paramType":"NUMBER","populationDescription":"Primary efficacy endpoint pre-specified only for participants treated in Cohort 1","reportingStatus":"POSTED","timeFrame":"From first dose of study therapy until 30 days after last dose (Assessed up to September 2016, approximately 90 months)","title":"Major Cytogenetic Response (MCyR) Rate","type":"PRIMARY","unitOfMeasure":"percentage of participants"}